Search

Search Results

• 

  Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients

  M. Romano, I. Pontikaki, M. Gattinara, I. Ardoino, C. Donati, P. Boracchi, P.L. Meroni, V. Gerloni

  278-285

  17-03-2014

  https://doi.org/10.4081/reumatismo.2013.682

  2632

  PDF: 1361

• Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis

  C. Botsios, P. Sfriso, A. Furlan, P. Ostuni, M. Biscaro, U. Fiocco, S. Todesco, L. Punzi

  32-37

  https://doi.org/10.4081/reumatismo.2007.32

  1638

  PDF: 739

• The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis

  L. Riente

  74-79

  https://doi.org/10.4081/reumatismo.2004.1s.74

  744

  PDF: 887
• 

  Are biological drugs safe in pregnancy?

  A. Calligaro, A. Hoxha, A. Ruffatti, L. Punzi

  304-317

  31-03-2015

  https://doi.org/10.4081/reumatismo.2014.798

  3723

  PDF: 2400
• 

  A short history of anti-rheumatic therapy - VII. Biological agents

  G. Pasero, P. Marson, B. Gatto

  185-194

  09-11-2011

  https://doi.org/10.4081/reumatismo.2011.185

  1487

  PDF: 1220
• 

  GISEA: an Italian biological agents registry in rheumatology

  G. Lapadula, G. Ferraccioli, C. Ferri, L. Punzi, F. Trotta

  155-164

  09-11-2011

  https://doi.org/10.4081/reumatismo.2011.155

  2299

  PDF: 1547
• 

  Long-term treatment with anakinra and canakinumab resolves patellar subchondral erosion in neonatal-onset multisystem inflammatory disease

  A. Leone, R. Manna, E. Verrecchia, M. Cipullo, D. Rigante

  53-55

  01-04-2019

  https://doi.org/10.4081/reumatismo.2019.1142

  1014

  PDF: 819

• Correlation between radiographic, echographic and MRI changes and rheumatoid arthritis progression

  M.A. Cimmino, M. Parodi, E. Silvestri, G. Garlaschi

  28-40

  https://doi.org/10.4081/reumatismo.2004.1s.28

  962

  PDF: 2929

• Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects

  C. Botsios, P. Ostuni, P. Sfriso, A. Furlan, U. Fiocco, D. Sgarabotto, S. Todesco

  224-235

  https://doi.org/10.4081/reumatismo.2003.224

  1109

  PDF: 2505